Tag: NASDAQ:KZIA

Additional Phase 2 data for paxalisib from Kazia Therapeutics for the treatment of glioblastoma revealed that the drug resulted in a mean overall survival of 15.7 months in patients compared to a control group.

Ref: https://seekingalpha.com

. . Kazia Therapeutics' share price was driven by strong buying in US-listed ADRs as the company's market capitalization moved from $ 75 million to $ 200 million since the Corporate Connect Research report was released.. . Corporate Connect biotechnology analyst Mark Sinatra updates the market after Kazia announces ASX for more Paxalisib data.

. . Kazia Therapeutics Ltd (KZIA) gained 194 points. 89% over the last 12 months. InvestorsObserver's proprietary rating system awards KZIA stock a score of 65 out of potential 100. This mattress is affected by a long-term technical score of 9

. . Sydney, Nov. 17, 2020 / PRNewswire / - Kazia Therapeutics Limited ASX: KZA is pleased; NASDAQ: KZIA, an Australian oncology company, said

. . The paxalisib phase 2 study is ongoing, with final data expected in the first half of 2021.